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During the last the few years, the number of peptide pharmaceutical drugs reaching the market has 
notably increased.  Drug based peptides have many advantages, such as high potency of action and 
limited off-target side effects that are not present in most small molecules.  However, oral 
bioavailability of peptides is a major obstacle that hinders the development of more therapeutic 
formulations.  Physiochemical properties of peptides, such as short plasma half-life, sensitivity to 
enzyme degradation and the tendency to undergo aggregation, are some of the main reasons for the 
lack of bioavailability. Enhancement of bioavailability can be achieved when the flexibility of peptides 
is reduced to a more defined stereochemical structure.  There are some approaches that can reduce the 
flexibility of peptide backbones to a more defined structure e.g. application of peptidomimetics and 
cyclic peptides.  Here, we have investigated another new tool that can lead us to the same goal. 
The purpose of this study was to investigate the possibility of modulating the secondary structure of 
short peptides.  This was envisaged via the application of a proline N-oxide moiety and by N-
methylation of the peptide backbone.  The major objectives for this study were:   
1. To synthesise a series of tetrapeptides to investigate the effect of proline N-oxide on their 
secondary structure.    
2. The effect of N-methylation of the amide bond on isomerization of the N-oxide peptide backbone 
in terms of cis- and trans-isomers and how it directs the potential hydrogen bonding interactions 
3. To study the effect of side chain bulkiness on the potential of hydrogen bonding interactions of 
the selected peptides. 
4. Analyses of the formed secondary structures with advanced NMR techniques.  
5. To perform a thermal coefficient NMR study on these molecules in order to obtain an improved 
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Chapter 1  
1 Introduction 
1.1 Peptides 
Peptides are short polymers formed from linking amino acids in a defined order.1  Ordinary amide bonds 
play the role of connector between these building blocks to form a long backbone.2  To join these 
building blocks to each other through amide bonds, an essential step is activation of the amine in one 
amino acids and the carboxylic group in the second one, followed by amide/peptide formation.  A peptide 
normally involves up to 50 amino acids, while biopolymers with more than 50 amino acids are called 
polypeptides/proteins.3  Natural amino acids largely exist in alpha (α) forms, these being organic 
molecules, with a carboxylic acid on one side of the central α-carbon and an amine group on the other.4  
In most cases one R-side chain is also attached to this carbon.  For the simplest natural amino acid, 
glycine, R = H.  It therefore is the only achiral amino acid in nature (Figure 1.1).5  
 
 
Figure 1.1.  Illustrative representations of natural amino acids: (1) α-amino acid and (2) the Fischer 
representation 
These chiral amino acids have non-superimposable mirror images, also called enantiomers.  Enantiomers 
have identical chemical and physical properties in the absence of an external chiral influence.  This means 
that both will have the same melting points, solubility, chromatographic retention time, IR and NMR 
spectra.  If the two enantiomers are mixed, the resulting sample will have different physical properties, 
such as melting point and solubility, but the chemical based properties such as chromatographic, IR and 
NMR behaviour will be unchanged.  This has an important consequence if we want to determine the 
proportion of the two enantiomers in a mixture: standard chromatographic and NMR methods must be 
modified to introduce an external chiral influence.  Only then will the enantiomers behave differently 
from each other and analysis be possible.6,7 
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There is one property in which enantiomers differ and that is the direction in which they rotate the plane 
of plane-polarized light.  This phenomenon of optical activity provides the basis for the nomenclature of 
enantiomers.  The enantiomer which rotates plane-polarized light in a clockwise direction ([ ]D = +14.6° 
in 1.5 M HCl) is denoted (+)-alanine while the other which has an equal and opposite rotation ([a]D = -
14.6°) is denoted (-)-alanine.  Since the rotations due to the individual enantiomers are additive, the net 
measured rotation may be used as a guide to the enantiomeric composition (provided the individual 
rotations are known).   
This (+) - (-) nomenclature must not be confused with the (R) and (S) system (Cahn-Ingold-Prelog).8  
Only the latter nomenclature enables us to describe the three-dimensional structure of a chiral compound.  
Although the Fisher (L and D) system is still used in Biochemistry it should not be confused with the (+) 
for Levo and (-) for Dextro.  There is no correlation between the (+), (-) and L, D.  All natural occurring 
α-amino acids are (S)-forms (or L-forms) with the exception of cysteine, which is normally in (R)-from.  
Amino acids are categorized into five different classes: acidic, neutral, basic, hydrophobic and 
hydrophilic.9   
1.2 Three dimensional (3D) structures of peptides 
Peptides or proteins have primary, secondary, tertiary and quaternary structures that contribute to the 
overall 3D structure.  Proteins and peptides illustrate remarkable and highly variant biological activities 
due to the ability of these intrinsically bendable chains to fold into well-ordered and compact secondary 
and tertiary structures.1  Linus Pauling, approximately half a century ago, realized that the unravelling of 
the secret interactions of these super molecules in biological processes and living cells depends on 
optimal information of their 3D structures.10  A small distinct change in secondary formations such as 
helices, sheets and turns, yield different configurations of tertiary and quaternary structures.11  A 
nomenclature has been defined for every peptide conformation with respect to their type of hydrogen 
bonds.12  However, there are several unique structures that do not fit in this categorization and called 
statistical coil.13-15 
1.2.1 Primary structure of peptides 
Generally, polypeptides or proteins are linear or unbranched polymers, which enables their primary 
configurations to be frequently identified in terms of the amino acids along their backbones.  Proteins are 
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often cross-linked (most often by disulfide bonds).  In addition, the primary structures also demand 
specifying the cross-linking atoms particularly when cysteine is involved in disulfide bonds.16 
1.2.2 Secondary structure of peptides  
Due to the existence of different amino acids in a peptide/protein with various side chains and functional 
groups, the linear form of the peptide/protein is generally not the most stable conformation.  Normally, 
stabilization occurs through hydrogen bonding interactions forming secondary structures such as helices, 
sheets and turns.   
1.2.2.1 Helices 
Helices are formed with regular folding and present as a corkscrew shape such as α-helix and 3.10 helix.  
In the majority of examples, peptides with this secondary structure prefer to turn clock-wise and form a 
right-handed helix.  This family can be differentiated into a few subcategories, depending on the 
periodicity of the helix.17  The α-helix is the most common configuration and its characteristics include 
first, the existence of a hydrogen bond between carbonyl group of residue (i) and amide of residue (i + 4) 
that presents a 13 membered ring.  Second, each loop has a length of 0.54 nm and involves 3.6 amino acid 
segments.  Third, the measured dihedral angels, Ψ and Φ are between 45 to 60 degrees.  This type of 
secondary structure is typically very densely packed and all the side chain of the amino acids point out of 




Figure 1.2.  α-helix18  
1.2.2.2 β-Sheet  
A β-Sheet is a commonly observed secondary structure in proteins or biopolymers, this being a plainer 
conformation that two residues being adopt it.  Similar to other types of secondary formations of peptides, 
hydrogen bonds play a critical role.  There are two different classes of β-sheets and both are formed 
through intermolecular hydrogen bonding interactions between at least two backbones (Figure 1.3).2  
These are the parallel β-sheet and parallel β-sheet.  The residues for the first are oriented in the same 




Figure 1.3.  (a) Anti-parallel β-sheet, (b) parallel β-sheet19 
1.2.2.3 Turns in peptides and proteins  
Turns are known as small secondary structures that form an “elbow” in peptides and in some cases can 
induce intramolecular β-sheet formation with two dominating fragments.  The internal hydrogen bonds 
stabilize the peptide backbones and the size of the “rings” is the basis for classification.  Different types 
of turns are categorized according to number of amino acids involved in the turn systems leading to δ-
turns (two amino acids) γ-turns (three amino acids), β-turns (four amino acids), α-turns (five amino acids) 
and π-turns (six amino acids).20  
The β-turn is the most important type due to its ability to influence the biological activity of a peptide.  
This advantage appears to originate from an improved fitting of peptide with this type turn as a ligand to 
the pocket of an enzyme or any other type of receptor. β-turns are characterised by the hydrogen 
bonding interaction between the residue (i) and residue (i + 3) in the same backbone.  Depending on the 
different dihedral angles that this bond can form in the sequence, ten types (Ι, Ι, II, II, III, III, IV, V, 





Figure 1.4.  A schematic representation of β-turns22  
All amino acids, with the exception of proline form peptides where the amides are mainly observed as 
trans-isomers.23-29  This bond arrangement has a profound effect on the secondary structure. The 
presence of proline in peptide sequence offers the possibility of cis/trans-isomerization of amide bond at 
the N-terminal part of proline.20  This process is known as the fundamental origin for peptide refolding in 
X-Pro peptides.30-39  Secondary structures can be organized by controlling the isomerization in these 
types of super molecules and the inclusion of amino acids with aromatic residues in the peptide backbone 
is a common technique to tune the cis/trans-isomerization through π-π and other electrostatic 
interactions.23,24,40-45   
More discussion on the secondary structure of peptides/proteins following in Chapter 2.  
1.2.3 Tertiary structure of peptides   
The tertiary structure is the final specific geometric shape that a protein assumes and is defined as a three-
dimensional conformation of a particular protein fragment.  The β-sheets and α-helices prefer to form 
compact globular structures.  Folding is controlled with the non-specific hydrophobic interactions, but the 
structure is fixed when parts of the protein domain are locked into place by specific tertiary interactions 
such as, hydrogen bonds, salt bridges, tight packing of side chains and disulfide bonds.  Disulfide bonds 




1.2.4 Quaternary structure of peptides   
Quaternary structures of peptides are the result of the arrangements of at least two folded or coiling 
protein molecules to form a single multi-protein complex where the individual units are kept together by 
weak intermolecular interactions.  Enzymes frequently form quaternary structures, for example the HIV 
protease consists of a homodimer where each of the C2 symmetric subunits consists of 99 amino acids.  
Holoenzymes form a class of enzymes with very much regular subunits of which the functional core is 
known as the catalytic subunit.47 
During the last decade, the number of peptide-based drugs approved by the Food and Drug 
Administration (FDA), USA, increased considerably.48-52  These molecules have attracted scientist’s 
attention due to advantages, such as e.g. high potencies of action and limited off-target side effects.53  
However, beside their benefits, some disadvantages prevent their more wide application in 
pharmaceutical science.  Low oral bioavailability and pharmacokinetic instability are the chief factors that 
have hindered the progress and development of peptides in the medicinal chemistry field of science.54,55  
The reason for these drawbacks originates from their physiochemical profile, such as their sensitivity to 
enzyme degradation, short plasma half-life.56-58  Peptide chemists have been attempting to eliminate these 
weak points with diverse strategies that will be reviewed in this chapter.   
1.3 Peptidomimetics  
The goal of peptidomimetics is to control the spatial disposition of amino acid functional groups that 
simulate a peptide structure through alternative molecules.59-62  Peptidomimetics inherit characteristics of 
their parent structures, but offer improved efficacy and stability in vitro against bacterial, fungal and 
eukaryotic origins.63  Application of these designed oligomers replicates or mimics is seen as an valuable 
tool for future drug discovery.64 
1.3.1 N-Methylated peptides  
One example of a widely used peptidomimetic approaches is the use of N-methylated amino acids.  This 
phenomenon also occurs in nature and there are well known examples of multiple N-methylated natural 
cyclic peptides,65 such as omphalotin, cyclosporine, (Figure 1.5) with important pharmacological and 




Figure 1.5.  Structure of omphalotin-A 
Chatterjee et al.66 reported that multi N-methylation in peptides not only increases receptor subtype 
selectivity, but also improves the oral bioavailability of the peptide.67  It has been reported that the N-
methylation of at least every second amino acid prevents the occurrence of proteolytic degradation on the 
peptide backbones.68,69  Poly N-methylated peptides have shown promising results in reducing the general 
cytotoxicity of peptide drugs due to the toxicity of degraded products.68  In a number of studies, the 
pharmacological properties of peptides have been altered through the application of N-methylation for a 
single amino acid.70  
1.4 Chemistry of N-oxides 
N-oxides are organic compounds with N-O- bonds and this bond is known to exhibit unusual dipolar 
covalent nature.22  The nitrogen atom can be sp2 (heteroaromatic nitrogen) or sp3 hybridized (aliphatic 
nitrogen) depending on the structure.19  N-oxide derivatives were first discovered as the oxidation 
products of tertiary amines before 1900.18  
There are three types of N-oxides, which differ in substituents that are bonded to the nitrogen atom 
(Figure 1.6).18  Their biological importance and applications as intermediates in organic synthesis 
motivated scientists to investigate these molecules.71  Heterocyclic N-oxides have also been utilized as 




Figure 1.6.  Three general forms of N-oxide compounds: (1) Heteroaliphatic N-oxide, (2) heterocyclic N-
oxide, (3) heteroaromatic N-oxide 
1.5 Analysis and conformational studies of peptides 
There are many approaches to investigate the secondary structures of peptides, the most common and 
efficient techniques being Nuclear Magnetic Resonance (NMR), Infrared (IR), Circular Dichrosim (CD), 
X-Ray Diffraction (XRD) and computational methods.  These are briefly outlined in the following 
sections.73-76 
1.5.1 NMR studies  
As discussed previously, hydrogen bonds are responsible for forming secondary structures in the peptide 
backbone77 and the chemical shifts of amide protons to the downfield region of the 1H NMR spectrum are 
useful for the determination of peptide organization.78  NMR active nucleuses are defined for isotope of 
elements that do not present nuclei with spin quantum number of zero.  1H1 and 
13C6 are two commonly 
nuclei with nuclei spin quantum numbers of ½ and are used in NMR spectroscopy.  15N7 has the same 
nuclei spin as 1H1 and 
13C6 but its signal is weak due to low natural abundance of this isotope for nitrogen.  
In addition, 15N NMR experiments are very helpful tools as nitrogen atoms are present in each residue of 
these biopolymers but the isotope enriched conditions should be used for the synthesis of biosynthesis of 
such systems.79  Another valuable tool is the Nuclear Overhauser Effect (NOE).  This experiments give 
through space proton-proton interactions and thus allow the observer to determine the distance between 
two nuclei up to about 5-6 A°.80   
1.5.2 Choice of solvent  
Solvent selection is important in NMR studies for these molecules.  Since peptides are amphiphilic in 
nature, the polarity of the solvents has a profound influence on the conformation of peptides.  When a 
polar solvent is utilized, the non-polar groups in the peptide are concealed inside the backbone and the 
peptides with more polar groups are exposed to the surface/solvent.  The opposite occurs when apolar 
solvents are employed.  The solubility of peptides depends on their sequences.  Typical apolar solvents 
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are Benzene-d6, CDCl3 and polar solvents such as DMF-d7, DMSO-d6, MeOD and D2O are often used.  
Due to the high dependence of peptide secondary structure to its environment, numerous conformations 
can be achieved by varying the solvent.73 
1.5.3 2D NMR techniques20  
2D NMR spectra offer valuable data that make them a powerful tool for analysing and detecting 
secondary structures in peptides.  In order to detect an unlabelled protein using this technique, a full set of 
two-dimensional NMR experiments is necessary.  When larger systems are analysed, it is much more 
convenient to use 15N labelled sources in the (bio) synthesis of the protein, as 2D correlations between the 
nitrogen and protons in close proximity (15N HSQC)81 provides invaluable information about the 
structure of the peptide/protein.  For a better understanding of application of each NMR experiment, a 
brief report is provided.  Note that the first methods all make use of through bond correlations, while the 
NOE related methods make use of through space correlations that is helpful for estimation of 3D 
structures.  
1.5.3.1 COSY: (Homonuclear Correlated Spectroscopy).  
The cross peaks in this experiment appear whenever the spin resonance at δ1 and δ2 are coupled to each 
other.82,83  Many advanced COSY based NMR experiments have been invented, such as DQFCOSY 
(double-quantum filtered), 84 COSY45,85 LR COSY86 and ECOSY.87  
1.5.3.2 TOCSY: (Total Correlation Spectroscopy).82  
This experiment utilizes a spin-lock for coherence transfer.  This process changes the coupled system to 
‘strongly coupled’, leading to cross peaks between all resonances in a coupled system.  Signal detection 
of weak coupling that is not detected in ordinary COSY can then be observed.   
1.5.3.3 INADEQUATE: (Incredible Natural Abundance Double Quantum Transfer 
Experiment).88  
2-Dimensional JC-C is a double quantum coherence experiment that produces a C-C correlation using 
1JCC.  
This experiment is probably the most powerful tool for structure-determination when compare to all 
others, but suffers from very low sensitivity.89  This disadvantage originates from low one-bond carbon-
carbon coupling constant that ranges from 30 to 80 Hz, approximately.80 
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1.5.3.4 CH-COSY or HETCOR: (Heteronuclear Correlation).108 
1H and 13C correlations give rise to unique coupling constants, denoted by JC-H.  In this method, vicinal 
(1JC-H) or geminal (
2JC-H) or long rang couplings 
3JC-H are detected.  Sensitivity is poor due to low 
population of the 13C nuclease, and it has been widely replaced with advanced methods such as HMQC 
and HMBC.90,91 
1.5.3.5 13C HSQC: (13C isotope Heteronuclear Single Quantum Coherence).90  
This method is a CH correlation experiment and is used to detect proton signals attached to 13C atoms.  It 
displays higher resolution in the C-dimension than does the related HMQC experiment, if the pulse-
calibration was done optimally.  See the comment in section 1.5.3.7 as well. 
1.5.3.6 15N HSQC: (15N isotope Heteronuclear Single Quantum Coherence).92 
This method is similar to ordinary HSQC except for using the natural abundance of the 15N isotope instead 
of 13C.  This experiment is one of the most important techniques for the investigation of secondary 
structures of peptides and proteins due to existence of NH for each residue with exception of proline.92   
1.5.3.7 HMQC: (Heteronuclear Multiple Quantum Coherence).90  
This method is very useful due to illustration of correlation between carbon and the attached hydrogen 
atom, similar to HSQC.  The difference between the two techniques is that the evaluation time of an 
HMQC, both proton and X magnetization (e, g X=13C) are allowed to evolve, whereas in HSQC only X 
magnetization is allowed to evolve.90  Therefore, HSQC is very depended on the calibration of the NMR 
pulses, while HMQC is not.90  When it is possible to correctly calibrate the NMR pulses, then HSQC will 
provide superior data.   
1.5.3.8 HMBC: (Heteronuclear Multi-Bond Connectivity).90 
This process acts similar to HMQC with the exception of not showing the one-bond correlations.  It is 
normally used to detect magnetization transformation between proton and carbon of a molecule over two 
or three bonds.93  This 2D experiment has shortcomings because the magnetization requires being transfer 
twice, which can create a delay in decreasing the peak signal intensity by usage of T1 and T2 relaxation.  
Note that C-X-H (X = N, S, O etc.) correlations are also observed.   
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1.5.3.9 NOESY, ROESY: (Proton-proton correlation mediated by dipolar coupling (NOE 
effect)).82 
Both of these experiments are very powerful NMR protocols to determine 3D structures of compounds, 
which could be small molecules or proteins.  It detects through space (intra and intermolecular) proton-
proton interactions. 
1.5.3.10 EASY-ROESY: (Efficient Adiabatic symmetrized Rotating Overhauser effect spectroscopy)94 
Sometimes, in the case of medium size molecules (Mw around 1000 gr.mole-1) the NOE correlation 
cannot be observed or the signal is very weak due to sign change of the NOESY.  In such this case 
EASY-ROESY is a more reliable technique.  This method is not only useful for measuring distances 
between two proton systems but can also be applied for measuring the exchange rate of a chemical 
reaction, if normal NOESY experiments cannot provide sufficient resolution.94    
1.5.3.11 EXSY: (Exchange Spectroscopy- the 2D equivalent of the Forsen saturation transfer   
experiment).85  
The transmission of magnetization is due to chemical exchange between A and B, rather than an NOE.  
EXSY uses an indistinguishable pulse sequence to the NOESY experiment, and is therefore subject to 
interference by NOE.  The magnetization transfer is the equivalent of a negative NOE and it has a long 
mixing delay in comparison to NOESY.85,95    
1.5.3.12 HOESY: (Heteronuclear Overhauser Effect Spectroscopy).96 
Through space correlations between heteronuclei and protons that are close to each other can be detected 
with this experiment.  The essential requirement for this NMR experiment is the significant relaxation for 
heteronuclei that can be provided with dipole-dipole interactions with nearby protons or other magnetic 
nucleus, enabling this heteronuclei to relax exclusively with failing of chemical shift anisotropy or 
quadrupolar mechanism.  This method is extensively used in the spectroscopy of organolithium reagents.   
The spin system in conventional correlation spectroscopy, COSY, is designed to transfer the α-proton 
magnetization between protons on the adjacent atoms.  It is clear that an α-proton transfers magnetization 
to a β-proton and the β-proton transfers to an α- and γ-proton, if any are available, with the same 
occurring for γ-proton with β, δ-protons.  This spin system is an invaluable tool to detect hydrogen atoms 
in α position, and simultaneously, the protons in the side chains of each amino acid residue in a peptide 
backbone.  In order to connect the different spin systems, the application of NOESY or ROESY that 
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transfer magnetization through space seems to be necessary.97  These experiments are able to show all 
cross peaks, which are close to each other with regards to the space, whether they are in the same spin 
system or not, provided that the molecule is rigid enough so that these interactions can be observed in the 
time scale of the NMR experiment.  Therefore, NOESY and ROESY NMR experiments are powerful 
instruments for establishing close contacts between individual amino acids in a single peptide or protein 
backbone.  These experiments have also been widely used to determine the secondary13 structures of 
biopolymers.  In most cases NOE data are provided to molecular dynamic experiments, in which these 
constraints are imposed to find the 3D structure of unknown proteins.81  
1.5.4 Hydrogen deuterium exchange and NMR thermal analysis experiments   
The involvement of protons in hydrogen bond interactions can be detected with both of these 
experiments.  Utilization of solvents that offer exchangeable deuterium atoms to the dissolved peptide in 
a NMR tube, such as CD3OD and D2O/H2O, are applied for this purpose.  Access of amide protons to 
solvents is prevented or retarded by intramolecular hydrogen bonding interactions.  The rate of 
disappearance of an amide proton peak is a measure of the strength of the hydrogen bond.73,98,99 
The same principle is applicable for thermochemical investigations of these biopolymers.  Generally, the 
amide proton involved in a strong hydrogen bonding interaction has a low temperature dependence 
coefficient (-dδ/dT < 3 ppb/K), while for ordinary amide protons; this value is more than -5 ppb/K.78,100-103    
1.5.5 Circular dichroism    
Circular dichroism (CD) is based on optical activities of chiral molecules that rotate differential left- or 
right-handed circularly polarized light.  Peptides are chiral molecules and rotate polarized light; the extent 
of rotation varies with wavelength. For peptides and proteins, the instrument is used to determine the 
basic conformation(s) present in macromolecules e.g. the secondary structure of peptides/ proteins or the 
handedness of DNA.104  Although information from CD spectra is limited in comparison to data from 
NMR or X-ray diffraction, it can be conveniently utilized as a preliminary guide for the nature of 
secondary structures of peptides.20,105  CD was invented by Aimé Cotton and the analysis is performed in 
highly dilute solutions (normally less than 1 mM, to avoid peptide aggregation) at the appropriate 
wavelength for UV absorption of the amide groups (180-230 nm).106  This instrument measures the 
ellipticity of peptides with polarized UV light.  Electron excitation of amide bonds (ππ*) can be 
observed and the absorption will vary based on the hydrogen or non-hydrogen bonded state of the amide.  
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This information provides reliable and valuable evidence about the shape of the secondary structure in the 
peptide backbone.104  The technique readily provides information about the whether a peptide contains α- 
helix, β-sheet and statistical coil conformation, but it cannot tell which part of the peptide contains it.105   
Peptides and proteins that possess few non-amino acid chromophores such as prosthetic groups do not 
display CD bands at wavelengths longer than 300 nm.20  Normally, the most prominent chromophore of 
proteins and peptides responsible for the CD spectrum is the amide group.20  There are two electronic 
transitions that can occur in the amide chromophore.  The (nπ*) transition presents a weak signal and 
appears in a negative band around 220 nm.  The energy (wavelength) of the amide (nπ*) transition is 
sensitive to hydrogen bond formation in the backbone.20,105  The (ππ*)transition is much stronger and 
displays a signal as a positive band around 192 nm and a negative band around 210 nm.20,105    
Furthermore, the characteristics of an α-helical secondary structure include a negative band at 208 nm, 
and a positive band at 192 nm.20,107  A β-sheet is characterized with a negative band at 216 nm and a 
positive band of comparable size close to 195 nm.20,108  A statistical coil secondary structure is 
characterized with a strong negative CD band just below 200 nm.20,108   These peaks can vary depending 
on the choice of solvent.    
The sample chamber of this instrument is made from quartz with a path length ranging between from 0.1 
to 10 mm.109  Shorter path lengths are preferred to limit parasite noise generated from solvent absorption.  
The choice of solvent in this experiment is very important and the selected solvent needs to be UV 
inactive in the chosen band for the peptide.  Solvents such as methanol (UV cut-off limit at 195 nm for a 
1 mm cell), trifluoroethanol (TFE) and a mixture of methanol and water are common solvents for CD 
measurements.  Other organic solvents e.g. THF, acetonitrile, chloroform or dichloromethane cannot be 
used for peptides of proteins due to overlap of UV absorption in the amide region.104 
This technique is a fast method, as it can provide an immediate result about the secondary structure 
adopted by the peptides.  A major disadvantage of this technique is that it cannot discriminate between 
amides that are, or are not involved in hydrogen bonding interactions.  Nevertheless, experimental CD 
curves of α-peptides are typical of specific or mixtures of secondary structures110 and observed peptide 
curves can be compared to published data.  Many reports on CD spectra of β-peptides appear in literature 
but this approach has rarely been used to detect secondary structure of peptides that possess unnatural 
amino acids, as the CD spectra are likely to differ from peptides involving natural amino acids only.   
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1.5.6 IR spectroscopy in solution   
Another interesting tool for the detection of intramolecular hydrogen bonds in peptides is to use IR in 
solution.  In the IR spectrum, the non-hydrogen bonded amides usually present peaks in area of more than 
3400 cm-1, while hydrogen-bonded amides appear in area of less than 3400 cm-1.  The solvent selection is 
a determining factor for use of this method, as the application of solvents that are able to form hydrogen 
bonds with the substrate will induce interference.111 
1.5.7 X-ray crystallography   
This is the most powerful and exact method for detecting secondary structure in peptides.  The only 
drawback factor for this technique is that crystal packing artifacts can cause deviation of the solution 
structure.  Nevertheless, in the majority of cases the crystal structure compare quite well with computed 
or the real structure.  It should just be noticed that large biomolecules are able to undergo dynamic 
movements and the crystal structure only present one specific ”snapshot”.81  Unfortunately, obtaining the 
crystal structure of a peptide is difficult, especially when the peptide backbone is highly flexible.13   
1.5.8 Computational studies  
The 3D conformation of peptides can be obtained from NMR, CD and XRD studies.  Another method 
that can supplement experimental results is molecular modelling of the peptide backbones.  The 
molecular dynamics (MD) calculations have been reported as a pioneer method for this purpose.112-115   
1.6 Thesis outline 
The rest of the thesis discusses the synthesis of N-benzylproline N-oxide peptides and their analysis 
utilizing NMR methods.  The aim of the study is to determine the structural behaviour of proline N-oxides 
incorporated into short peptides. The formed secondary structures of these biopolymers have been 
investigated.  The strategy followed to unravel the effect of the N-oxide on the secondary structure was to 
make a logical comparison between the same peptide with, and without N-oxide modification.  We have 
chosen two types of peptides for this purpose, one which is proposed to be more flexible and with amino 
acids that are known to induce turn structures, and a second that are less flexible and with amino acids 
that are known to prevent turn structures.  In addition to that, selective N-methylation of amides bonds 
was also introduced to study the capability of N-oxide peptides to form quasi β-turn as is a potential 
valuable new type of secondary structure.  Information about the conformations of the peptides was 
obtained from 2D NMR experiments (NOE) and thermal analysis of the 1H NMR spectra of these 
molecules.   
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1 Proline N-oxide: Manipulation of the 3D Conformation of Linear 
Peptides 
1.1 Introduction  
During the last the few years, the number of peptide pharmaceutical drugs reaching the market has 
notably increased, as is indicated by the USA Food and Drug Administration’s approval of six new 
peptide-based drugs in 2012.1  This represents 15% of total new drug approvals, and peptides are 
starting to compete with small molecule drug medications (about 34% in 2012)2 that dominated the 
market in the previous century.  The recent success of peptide-based drugs is fuelling the interest of 
pharmaceutical companies and research groups in this field, which will lead to further development 
of peptides as therapeutics.2-5  Drug based peptides have many advantages, such as high potency of 
action and limited off-target side-effects that are not present in most small molecules.6  However, 
oral bioavailability of peptides is a major obstacle that hinders the development of more therapeutic 
formulations.7,8  Physiochemical properties such as short plasma half-life, sensitivity to enzyme 
degradation and the tendency to undergo aggregation are some of the main reasons for the lack of 
bioavailability.9-11  Enhancement of this property can be achieved when the flexibility of peptides is 
reduced to more defined stereochemical structures.9-11   
The bioavailability of peptides can also be increased by selective N-methylation of some of the 
amide nitrogen atoms in the backbone,12-14 as enzymes seem unable to hydrolyse such bonds.15  In 
addition, N-methylation dramatically increases aqueous solubility of the peptide (as much as 1000 
fold for one N-methylation).15  However, a more remarkable result is that this modification 
simultaneously improves the lipophilicity,13 proteolytic stability and conformational rigidity of these 
peptides.12-14 
The amide bond of peptides containing natural amino acids appear mostly in the trans-conformation, 
with the exception of the amide bond at the N-terminal of proline.16-21  In addition, proline also 
induces peptide folding, yielding secondary structures with β-turn or alpha helix character.22-28  This 
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proline amide bond gives relatively high cis-trans isomerization (3-5% cis-isomers).29  The 
availability of aromatic rings in normal peptides is known to be an important factor for an increase in 
the percentage of cis-proline isomers through intermolecular π-π interactions which severely restrict 
the conformational freedom of the peptides.23,24,30-35  Studies have indicated that aromatic groups in 
short peptides can interact with proline through potentially tuneable aromatic π-electron donor/prolyl 
acceptor interactions.16,36-41  The rotational energy barrier for proline cis/trans-isomerization is 
normally in range of 16-20 kcal/mol.42  In some cases values as low as 8 kcal/mol have been 
recorded.43,44  It appears that side chain π-π stacking contributes to this lower than usual rotational 
barrier.   Changing the cis/trans-isomerization state can alter fundamental control of peptide 
folding.30,45   
It is important to note that, energy barriers between 15-20 kcal/mol can be overcome at room 
temperature and for this reason proline is often used for folding of peptides.46,47  Interestingly, 
individual cases have been reported where certain proline containing peptides gave up to 50% and 
also complete cis-conformations.48  This isomerization is the rate-limiting step in the refolding of 
denatured proteins.49-63  However, there is no definite rule with respect to the equilibrium of cis- and 
trans-isomers of peptides, but solvent polarity has an influence.  A polar solvent, such as DMSO 
with a large dipolar moment (3.96 D), favours cis-isomers (Kt-c = 92 at 293 K), while less polar 
solvents, such as water (1.85 D), induce more trans-character (Kt-c = 151 at 293 K).
64,65  The 
isomerization ratio can be analysed with NMR spectroscopy from characteristic Nuclear-Overhauser 
(NOE) proton-proton distances.49,66-68  
Replacement of the hydrogen on amides in peptides with a methyl group, will diminish hydrogen 
bonding interactions between peptide backbones,15 which is responsible for β-sheet formation.14,69-
73  Other alterations of the secondary structure may also occur since cis/trans isomerization of the 
amide bond increases for N-methylation.  This isomerization is sometimes used to regulate the 
function of the peptide.74-77  As is the case for natural peptides there appears to be no particular rule 
that predicts or governs the ratio of cis- and trans-conformations of N-methylated peptides.  These 
types of molecules generally present multiple cis/trans amide bond isomers, as is evident from 
recently reported NMR data.17,68,78-84  Integration of the methyl groups in the proton spectra also 
reflected the cis/trans ratio.78-80 In this type of ratio measurement, the experimental error 
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is approximately ±15 %.78  According to previous reports on N-methylated peptides, the 
population of cis-isomers are generally higher at lower temperatures, but decrease at room 
temperature,78,85 this equilibrium being highly depended on the local environment, such as peptide 
backbone or the folding thereof.64  It was demonstrated in previous spectroscopic and computational 
studies on N-methylated polypeptides, that the ratio between the populations of cis- and trans-
isomers varies and is highly depended on temperature, solvent and the type of amino acids in the 
backbone.78,79  The isomerization energy barriers for small N-methylated model peptide systems 
(tertiary amides) were calculated with quantum mechanical methods and measured with NMR 
spectroscopy experiments and was found to be between 12-22 kcal/mol (depending on the solvent 
system),43,86 while for secondary amides (non-methylated amides) ranged between 18-22 kcal/mol.86     
The synthesis of structurally constrained peptides can be achieved with several strategies, the most 
popular being cyclisation of the peptide.87  Cyclic peptides can be formed by several approaches, 
such as head-to-tail, head-to-side chain, side chain-to-tail or side chain-to-side chain, among 
others.88  Synthesis of self-assembled peptides, which includes non-covalent and reversible 
interactions, such as van der Waals, hydrogen bonds, hydrophobic and aromatic π-π stacking, is 
another way to form secondary structures, such as turns, helices, and sheets of self–assembled 
material (nanotubes).89-96  
A γ-turn involves seven atoms in the peptide backbone (Figure 2.1) and is characterized by the 
existence of hydrogen bond interaction between carboxyl group of residue (i) and NH of residue (i + 
2).97  The presence of γ-turns is far less abundant in peptides and proteins than β-turns.97-99  The 
profile of this axial or classical γ-turn in Ramachandran plot is defined as ϕ= +75°, ψ= -65°, whereas 
when ϕ= -75° and ψ= +65° it is known as the equatorial or inverse form.97  A normal H-bond 
distance (3-5 Å) is required for stabilization of folded peptides containing this turn.97  Normally, 
some variation of the ω value (|ω| ≈ 10°) is also necessary for formation of the hydrogen bond.97,100 
One of the most eminent secondary peptide structures is the β-turn, which consists of at least four 
amino acids,101 with residue numbers (i), (i + 1), (i + 2), (i + 3) (Figure 2.1).  A general 
characteristic of β-turns is the occurrence of a hydrogen bonding interaction between CO group of 
first amino acid (i) with NH (i + 3).101-104  There are four parameters that confirm the existence of a 
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β-turn.  First, adequate hydrogen bond interactions, which provide a distance around 7 Å for dcritical 
between atoms Cα(i) and Cα(i + 3).101,105-107  Second, the virtual torsion angles (τ), defined by 
atoms Cα(i), Cα(i + 1), Cα(i + 2), Cα(i + 3), should fall between -90° ≤ τ ≤ +90°.101,105-107  Third, 
the distances between the carbonyl oxygen of residue (i) and NH of residue (i + 3) should be less 
than 4 Å.101,108  When all four criteria are met, the peptide exhibits tight β-turn characteristics.  
                              
                                        γ-turn                                                β-turn 
Figure 2.1.  Criteria used in the identification of γ- and β-turn characteristics97,100,101 
Proline is known to be an active β-turn inducer when placed in the (i + 1) position in peptide 
backbones.  In an effort to find alternative sources of β-turn inducers, our group has previously 
reported pentacycloundecane (PCU) and trishomocubane amino acid cage compounds.101,109,110  
Herein we present another new tool to form β-turns by taking advantage of the capability of the N-
oxide moiety to perform strong hydrogen bond interactions when introduced to proline. 
Significant progress in establishing the conformation of peptides and proteins from NMR studies has 
been achieved from the relationship between chemical shift and structure.111  In addition, 
computational methods have been employed as useful tools to supplement these experimental 
studies, particularly in the absence of X-ray data.112-115  
O’Neil and co-workers studied the conformational effect of proline N-oxides [P(NO)] using either an 
N-alkyl-P(NO)-amide or N-alkyl-P(NO) containing dipeptide and showed that hydrogen bonding 
takes place mainly through a six-member ring (Figure 2.2).  In addition it was reported that the 
formation of hydrogen bond between amide protons further away and the N-oxide unlikely and if 




Figure 2.2.  Proposed N-oxide hydrogen bonding arrangement by O’Neil and co-workers117 
Since the NO- oxygen is replacing the normal carbonyl oxygen as per the standard turn definition, 
the observed turn with the N-oxide cannot be classified as a normal γ- turn.  The number of atoms 
involved in a classical γ-turn is 7.  In this quasi-turn case it consists of 6 atoms. 
We decided to expand on this study, by investigating the scope and limitations of a tertiary proline 
N-oxide, combined with selective N-methylations as modulators of tetrapeptide conformations 
through hydrogen bonds with neighbouring amide NH protons.   
Two different families of peptides were earmarked.  The sequence of the first was chosen based on 
optimal β-turn characteristics and the second with amino acids known not to induce turns.  Several 
tetrapeptides, which contain N-oxide-N-benzylproline, as N-terminal residue (Figure 2.3) were 
prepared, and their conformational preferences were studied with NMR spectroscopy.  Proline 
followed by glycine is known to be a strong β-turn combination.29  For the first peptide family we 
therefore chose [Bz(NO)PGNF].  Asparagine (N) and phenylalanine (F) are also known to assist 
with turn formation.118,119  For the second peptide family we selected [Bz(NO)PIVQ].  Both 
isoleucine (I) and valine (V) are known to prevent β-turn formation of short peptides.118-121  
Glutamine for the final residue was chosen since it is bulkier than asparagine and it also has an 










Figure 2.3.  N-oxide-proline tetrapeptides. [Bz(NO)PGNF], [Bz(NO)PMeGNF], [Bz(NO)PIVQ] 
and [Bz(NO)PMeIVQ]   
In the case of the N-oxide and N-methylated peptides, potential hydrogen bond interactions between 
the (i + 2) amide proton and the N-oxide group is possible.  Since the NO- oxygen is replacing the 
normal carbonyl oxygen as per the standard β-turn definition (see Figure 2.1 for the definition), 
such a turn with the N-oxide cannot be classified as a normal β-turn.  The number of atoms involved 
in a classical β-turn is 10.  In this quasi-turn case, the number of atoms is 9. 
1.2 Results and discussion 
Peptides were synthesized via a solid-phase approach on 2-chlorotrityl-chloride (CTC)-resin with 
HBTU/DIEA as a coupling cocktail using Fmoc protection of the amino groups.  For better control 
of the synthetic process, previously prepared N-benzylproline was incorporated as the last building 
block.122  At the end of the synthesis the peptides were cleaved from the resin with 40% TFA in 
DCM and the tertiary amine of the proline was selectively oxidized using (m-CPBA) and K2CO3 in 
DCM at –72°C (Scheme 2.1).  Peptides were purified via a semi-preparative HPLC with a C8 




Scheme 2.1.  Synthetic strategy used to prepare the proposed peptides  
NMR techniques were employed to identify the hydrogen bond acceptor for NO oxygen of the 





1.2.1 Comparative structural study on the peptides designed for optimal β-turn 
characteristics 
The four structures for the first family of peptides are presented in Figure 2.4.  
 
Figure 2.4.  Peptides theoretically designed for optimal β-turn characteristics   
Complete NMR assignments of all peptides were made utilising 2D NMR techniques.  These 
assignments are presented in the Supplementary Material.  Three aspects were monitored: (a) the 
ratio of cis/trans isomerization, (b) deshielding of the amide protons (NH) due to through space 
deshielding of the NO- oxygen and (c) NOE interactions characteristic of β-turns.   
From the NMR data, it was clear that at least two dominant conformations were present in 2a and 
2b.  These are ascribed to cis/trans isomers of the N-methylated peptide bonds, as shown in Figure 
2.4.  The cis/trans ratios were determined from the integration of distinct proton signals.  A 
summary of these results is presented in Table 2.1. 
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Table 2.1.  Cis/trans isomerizations of proline amide bonds at the C-termini of peptides 1 and 2 at 
room temperature.  Data obtained from proton NMR integrations in DMSO-d6. 
Symbol Sequence cis % trans % 
1a BzPGNF 0 100 
1b Bz(NO)PGNF 0 100* 
2a BzPMeGNF 47 53 
2b Bz(NO)PMeGNF 29 71 
* This sequence shows two conformations (See Table 2.2).  
 Comparison between compounds 1a and 1b 
Peptide 1a displayed only the trans-isomer.  After assigning each peak in 1H NMR and 2D NMR, it 
seemed that this molecule shapes somehow that fits on stable hydrogen bonding pattern.  
Peptide 1b appeared as two conformers (major and minor).  ROESY NMR data indicated that both 
conformers are trans with respect to the amide bonds (Figure 2.5).  The proline α-proton gives an 
NOE interaction with the (i + 1) NH proton.   
 
Figure 2.5.  Detection of both trans conformers by usage of ROESY in 1b, [Bz(NO)PGNF] peptide 
at room temperature.  The water peak is suppressed. (Solvent: DMSO-d6 )  
It should be noted that the percentage of minor conformation in 1b was quite small (15%), hence 
only a weak NOE interaction was observed.  An analysis of these two conformations was made from 
the NMR data and is presented in Table 2.2.  
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Table 2.2.  NMR chemical shifts of amide groups in 1a and 1b.  Chemical shifts are reported in 
ppm.  (Solvent: DMSO-d6) 




NH-Gly 7.98 10.78 8.02 
NH- Asn 8.23 8.55 8.19 
NH-Phe 7.48 7.86 7.92 
* Two conformations were observed.  The major conformation appeared to exhibit some γ-turn character (NO- and 
prominent (i + 1) NH interaction).  The minor conformation is possibly a more extended peptide conformation (lack of 
NO
-
 and NH (i + 1) interaction).   
The 1H NMR data indicates that the first amide (i + 1) of the major isomer of 1b prefers to engage 
with the N-oxide moiety.  This is evident from the downfield shift of the (i + 1) amide proton in the 
proton NMR spectra.123  This shift is most possibly the result of intramolecular hydrogen bonding 
interactions between the amide proton and the N-oxide oxygen atom, causing through space 
deshielding and suggests γ-turn characteristics.29  On the other hand, this interaction is absent for the 
minor conformation, suggesting it does not include the quasi γ-turn.  The variable temperature NMR 
data indicated that the major isomer (quasi γ-turn) begins to loose the turn structure and in favour of 
perhaps a more extended structure upon increasing the temperature.  Protein structures are stabilised 
through intramolecular hydrogen bonding and with increasing temperature this interaction is 






Figure 2.6.  A thermodynamic study of 1b, [Bz(NO)PGNF].  Chemical shifts are reported in ppm. 
Major (M) product converts to minor (m) product with increasing temperature. (Solvent: DMSO-d6).  
 Comparison between compounds 2a and 2b  
Peptide 2a includes N-methylated glycine as the first amino acid following N-benzylproline.  As 
expected, both cis and trans-isomers exist and the cis/trans isomerization ratio is 47:53 at room 




Figure 2.7.  Ratio between cis and trans-isomers in 2a, (BzPMeGNF) (47% cis, 53% trans) at room 
temperature. (Solvent: DMSO-d6) 
The isomers were verified from the ROESY data (Figure 2.8).  It is clear that the trans-
conformation should experience a through space NOE interaction between the proline Hα and the 
methyl protons (N-Me).  This was absent for the cis-isomer due to the methyl protons (N-Me) 
pointing in the opposite direction.   
 
Figure 2.8.  ROESY study for the detection of cis- and trans-isomers in 2a, (BzPMeGNF) at room 
temperature.  The water peak is suppressed.  (Solvent: DMSO-d6)   
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With regards to 2b, The complete NMR elucidation of the cis-isomer could not be achieved due to a 
low signal to noise ratio and overlapping of signals with the trans-isomer.  The cis-isomer (29%) 
was not involved in hydrogen bond interaction (Figure 2.11). 
For the trans-isomer (71%) of 2b, the backbone amide proton of asparagine (i + 2) was de-shielded 
(about 9 ppm) due to the close proximity of the N-oxide oxygen (Figures 2.9 and 2.10) which 
causes a moderate hydrogen bonding interaction.  This result suggests that the N-oxide moiety can 
be used as a β-turn inducer.  However, as mentioned before this turn is not a classical β-turn (Figure 
2.1)29 but rather a quasi, or perhaps a new type of β-turn.  This turn was confirmed by correlations 
from ROESY NMR (Table 2.3).  
 
Figure 2.9.  NMR proton chemical shifts in the down field region for 2a, (BzPMeGNF) and 2b, 




Figure 2.10.  ROESY study for detection of cis- and trans-isomers in 2b, [Bz(NO)PMeGNF] at 
room temperature.  The water peak is suppressed.  (Solvent: DMSO-d6) 
 
 
Figure 2.11.  Ratio between cis- and trans-isomers in 2b, [Bz(NO)PMeGNF] (29% cis, 71% trans) 
at room temperature.  (Solvent: DMSO-d6) 
ROESY data for trans-2b are presented in Table 2.3.  The correlations between H-21 with H-11, H-
14 and H-15 as well as the correlations between H-26 and H-20, H-17 provide convincing proof for 
the presence of a quasi β-turn in 2b.  These correlations clearly display that the intramolecular 
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hydrogen bonding interaction between NO- and backbone asparagine NH is able to induce folding of 
the peptide (Table 2.3).  
  
Table 2.3.  NOE correlations for trans-2b at room temperature in DMSO-d6, [Bz(NO)PMeGNF]  
Atom Number Correlated hydrogen atoms 
18 15 




 Comparison between compounds 1b and 2b  
Due to the flexible nature of glycine in the peptide backbone and the absence of a chiral centre, the 
hydrogen bond interaction between the N-oxide oxygen and the amide proton appears to be less 
prominent in 1b.  When the first hydrogen bond donor in position (i + 1) is blocked with a methyl 
group as in the case of 2b, the possibility of hydrogen bonding between the N-oxide moiety and this 
amide group (i + 1) is eliminated.  The shielding effect of the NO- on the corresponding amide NH 
protons can be seen in Figure 2.12.  For 1b, the hydrogen bond interaction between the amide 
proton of glycine (i + 1) and the negative NO- oxygen at the N-terminal of proline provides a 
stronger deshielding interaction, compared to the amide proton of the more distant asparagine (i + 2) 




Figure 2.12.  Estimation of the hydrogen bonding potential in 1b, [Bz(NO)PGNF] and 2b, 





1.2.2 Comparative structural study on peptides designed for minimal β-turn 
characteristics 
The four structures for the second family of peptides are presented in Figure 2.13.  Complete NMR 
assignments for all peptides were made utilising 2D NMR techniques.  These assignments are 
presented in the Supplementary Material. 
 
Figure 2.13.  Peptides designed for minimal β-turn characteristics 
The peptides structures were studied using 1D and 2D NMR techniques, and full elucidation of each 
peptide was achieved.  Three aspects were again monitored: (a) the ratio of cis/trans isomerization 
and (b) deshielding of the amide NH protons due to through space deshielding of the NO- oxygen 
and (c) prominent NOE interactions.  As expected, only trans amide conformations were observed 
for the normal peptides 3a and 3b.  It was clear that at least two conformations were presented for 4a 
and 4b, this being ascribed to cis/trans-isomers of the N-methylated peptide bonds, as illustrated in 
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Figure 2.13.  The cis/trans ratios were determined from the integration of distinct proton signals.  A 
summary of these results is presented in Table 2.4.  
Table 2.4.  Cis/trans isomers of the proline amide bonds at the C-termini at room temperature.  Data 
obtained from proton NMR integrations are in DMSO-d6.  
Symbol Sequence cis % trans % 
3a BzPIVQ 0 100 
3b Bz(NO)PIVQ 0 100 
4a BzPMeIVQ 40 60 
4b Bz(NO)PMeIVQ 77 23 
 Comparison between 3a and 3b 
Comparisons of the NMR chemical shifts for NH in the (i + 1) positions were made.  A four-ppm 
difference between the isoleucine amide proton signals (Figure 2.14, 3a appears at 7.85 ppm and 3b 
at 12.05 ppm) is evidence for the presence of an intramolecular hydrogen bonding interaction for 3b.  
This through space deshielding effect was clearly an indication of a tight hydrogen bond interaction 
between the NH (i + 1) proton and the negatively charged NO- oxygen atom.  These results are in 
agreement with the reports by O’Neil et al.116,117  This is a quasi γ-turn. No extraordinary ROESY 
correlations between proline and the rest of the peptide were noticed in either case.  
 
Figure 2.14.  NMR proton chemical shifts in the down field region for 3a, (BzPIVQ) and 3b, 
[Bz(NO)PIVQ] at room temperature  (Solvent: DMSO-d6) 
In order to analyse the versatile nature of this NH to NO- hydrogen bonding interaction, the N-
methylation of the isoleucine amide nitrogen (i + 1) was investigated. 
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 Comparison between 4a and 4b 
From Table 2.4, it is clear that N-methylation induces cis- and trans-isomers for both peptides (4a 
and 4b). In 4a, the cis-isomer is 40% and the trans-isomer 60% according to the proton spectrum at 
ambient temperature (Figure 2.15).  Note that the cis-isomer is favoured by the polar NMR solvent 
(DMSO-d6).  
 
Figure 2.15.  Ratio between cis- and trans-isomers in 4a, (BzPMeIVQ), (40% cis, 60% trans) at 
room temperature.  (Solvent: DMSO-d6)  
Both isomers were observed in a ROESY NMR experiment, as is shown in Figure 2.16.   
 
Figure 2.16.  ROESY study for detection of cis- and trans-isomers in 4a, (BzPMeIVQ) at room 
temperature.  The water peak is suppressed (Solvent: DMSO-d6)   
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Further investigations were conducted to observe if any folding occurred in 4a.  No extra-ordinary 
ROESY correlations were observed, which indicates that the distance between protons of two 
different residues in the same backbone is more than 5 Å or the system is too flexible to observe 
NOE interactions.  This evidence suggests that the backbone does not form any stable turn or fold. 
Similarly, the NMR of 4b presented multiple isomers.  The ratio could not be accurately established 
from the N-Me protons, due to overlap.  The glutamic acid side chain amide protons revealed a 
77:23 ratio in favour of the cis-isomer (Figure 2.17).  Confirmation of the isomer assignments was 
achieved when it was established that the NH proton of valine (i + 2) at about 9.9 ppm experienced 
through space deshielding due to intramolecular hydrogen bonding with the N-oxide moiety (Figure 
2.18).  Further evidence for this elucidation was obtained from the ROESY spectra of 4b (Figure 
2.19).  
 
Figure 2.17.  Ratio between cis- and trans-isomers in 4b, [Bz(NO)PMeIVQ] (77% cis, 23% trans) 




Figure 2.18.  NMR proton chemical shifts in the down field region for 4a, (BzPMeIVQ) and 4b, 
[Bz(NO)PMeIVQ] at room temperature.  (Solvent: DMSO-d6) 
We initially chose isoleucine and valine because they have been reported to prevent β-turns.118-121   
This turn (cis-4b) appears to be a quasi β-turn, created by the N-oxide moiety, in the presence of 
these residues.  To our knowledge this is the first example of such a secondary structure.   
 
Figure 2.19.  ROESY studies for the detection of cis- and trans-isomers in 4b, [Bz-P(NO)-MeI-V-
Q].  The absence of a NOE correlation between the cis-N-methyl group and the proline Hα, assisted 
to differentiate between the conformations. The water peak is suppressed.  The spectra was obtained 
at room temperature.  (Solvent: DMSO-d6)  
Development of a quasi β-turn secondary structure (see Figure 2.13) in the presence of bulky amino 
acids, such as isoleucine and valine, is therefore a novel and unique achievement, and appears to 
only occur as result of the P(NO) in the peptide backbone.   
The β-turn character of cis-4b was confirmed with several long-range correlations from ROESY 
NMR, as demonstrated in Table 2.5 (the ROESY spectra including correlations are available in 
Supplementary Material).  Convincing evidences for the presence of a quasi β-turn in 4b are: (a) 
correlations between H-20 with H-12, H-17 and H-18, (b) a correlation between H-23 with H-12 and 
(c) relation between H-24 and H-12.  (d) Existence of NOE correlations between H-26 and H-15, H-
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17 and H-18 (e) a correlation between H-28 and H-12.  These correlations support the presence of 
intramolecular hydrogen bonding interactions between NO- and the backbone asparagine NH, 
induced folding of the peptide.  
 
 
Table 2.5.  NOE correlations of cis-4b, [Bz(NO)PMeIVQ], at room temperature in DMSO-d6  
Atom Number Correlated hydrogen atoms 





 Comparison between 3b and 4b 
The potential of the N-oxide group to create hydrogen bonding can be clearly seen in 3b and 4b.  
The amide proton of isoleucine (i + 1) in 3b appeared at about 12 ppm, whereas the amide of valine 
(i + 3), registered at approximately 10 ppm (Figure 2.20).  These results indicate that the distance 
between the hydrogen bond donor and acceptor (N-oxide) plays an important role in peptides with 
sterically hindered amino acids.  In this case it forms a very strong hydrogen bond between NO- and 
the closest amide as was evident from the large deshielding effect on the (i + 1) amide proton in 3b 
(Figure 2.20).  The trans-conformation of 3b and the steric hindrance imposed by isoleucine and 
valine appeared to prevent any interaction between the other amide protons and the NO-.  In contrast, 
the N-oxide moiety in 4b revealed a 77% cis-conformation which was able to overcome this 




Figure 2.20.  Estimation of hydrogen bond potential, based on NMR shift in 3b, [Bz(NO)PIVQ] 




1.2.3 Thermal coefficient NMR investigation:  Nature of the hydrogen bond interaction 
between the proline N-oxide and the backbone NH protons. 
As discussed before, the presence of this hydrogen bond could be detected by observing the 
chemical shifts of backbone amide protons in the 1H NMR spectra.  Furthermore, analyses of the 
thermal behaviour of hydrogen bonds in the peptides utilizing NMR are an elegant technique to 
study the exact nature of this interaction.124-129  Normally, the intramolecular hydrogen bonding 
interactions between a hydrogen bond donor (amide proton) and the acceptor (carbonyl oxygen) in a 
peptide is disturbed at higher temperatures; the amide proton signals also experience a downfield 
shift (less through space deshielding) in the 1H NMR spectra in aprotic solvent systems.124-129  In 
aprotic solvents such as DMSO-d6, when -Δδ/ΔT > 5
1 ppb/K, the typical intramolecular peptide 
hydrogen bond is absent if the amide protons are solvent-exposed.  When -Δδ/ΔT < 3 ppb/K the 
amide proton is shielded from the solvent, due to hydrogen bonding with any carbonyl oxygen 
atom.124-129  
The plotted -Δδ/ΔT graphs (available with the Supplementary Material) for peptides and N-
methylated peptides in DMSO-d6 confirmed that no intramolecular hydrogen bonds exist for 
peptides 1a–4a.  The presence of hydrogen bonds between the NO- moiety and hydrogen-bonded 
NH in different N-oxide peptides 1b – 4b were also investigated with this method.  These molecules 
present a low -Δδ/ΔT value (-2.64 to 0 ppb/K) for amide protons involving hydrogen bonding with 
the N-oxide moiety.  When these amide protons are not involved in hydrogen bonding interactions, 
the values are > 4 (ppb/K).  The results for peptides 1b – 4b are presented in in Figures 2.21, 2.22, 
2.23 and 2.24.  The negative value for -Δδ/ΔT (which renders positive slopes) called for a more in 
depth analysis.  
Langner and Zundel130 reported that the acid-base equilibria (AH---B-  A----HB) plays a very 
important role in the proton transfer process.  Proton transfer systems are characterized by the 
following:  i) All systems of this family possess the same hydrogen bond donor (AH) and the 
acceptors (B) are also similar molecules, the only difference is between the pKa of B.  ii) Or the 
acceptor (B) is always the same and the donors (AH) are similar molecules and the only differences 
are between their pKa values.   
                                                 
1 The slopes of these graphs for normal peptides are usually negative. 
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In such systems, ΔpKa is defined as the [pKa B - pKa AH].
131,132  Langner and Zundel130 have 
explored the interaction between a strong acid (AH) such as dimethylphosphinic acid (DMP) and 
methanesulfonic acid (MSA) with different derivatives of N-oxide molecules as the base.  It was 
found that for systems with an increasing ΔpKa, the proton from the hydrogen bond donor moves 
closer to the acceptor, which causes deshielding of the mentioned proton.  For example, in the case 
of MSA (ΔpKa = 2.5) the proton resides with MSA, while for DMP (ΔpKa ≈ 6.5), the proton is 
shifted completely to the hydrogen bond acceptor and the signal appears in the up field region of the 
1H NMR spectra.  These results are also consistent with an entropy (S) argument since with 
increasing ΔpKa, the structures possess more polarity, and hence, a well-ordered environment can be 
achieved.130  Therefore, shifting the proton in the direction of the acceptor is due to increasing the 
amount of the negative entropy.   
The hydrogen bond donor (AH) in this study was hydrogen-bonded amides and the acceptor (B) role 
was played by N-oxide moiety.  The proton chemical shift for several of these amides appeared in a 
region that is known for acid functional groups and this gives strong evidence for the acidic 
character of such amides.  The ΔpKa value for this system (amide and N-oxide) is expected to be 
low.  It is important to note that ΔpKa is directly related to temperature according to the Van’t Hoff 
and Helmholtz equations.  
With this background in mind, the amide proton NMR shifts were measured at different 
temperatures in order to determine the hydrogen bond character between that and the N-oxide 
oxygen atom.  
For trans-1b, [Bz(NO)PGNF], the -Δδ/ΔT graphs are presented in Figure 2.21.  The hydrogen bond 
interaction between the amide proton (i + 1) and the N-oxide oxygen renders a positive slope 
(gradient = 2.64).  This result is typical of normal acid-base equilibria behaviour.130  The slope of 
this gradient suggests that the proton transfer in this system was temperature sensitive and the down 
field proton shift (≈10 ppm) suggested that the amide proton had probably started to transfer to the 
donor atom (N-oxide oxygen).  There are two opposing factors playing a role in this case.  First, the 
ΔpKa value is directly proportional to the temperature and this causes the amide proton (i + 1) to be 
transferred to the N-oxide oxygen atom.  Second, the glycine residue possesses less steric hindrance 
and causes greater flexibility of the peptide at higher temperatures.  This flexible nature makes 






                                                 (2)                                                      (3) 
(1) HN-Gly (-Δδ/ΔT= -2.64 ppb/K)2, (2) HN-Asn (-Δδ/ΔT= 4.56 ppb/K), (3) HN-Phe  (-Δδ/ΔT= 
4.50 3ppb/K) (R2 > 0.997 for all graphs)  
Figure 2.21.  The hydrogen bond investigation with thermal coefficient plots for each amide protons 
of trans-1b, [BzP(NO)GNF].  (Solvent: DMSO-d6), (temperature: 293-333 K)  
The non-hydrogen-bonded amides (i + 2 and i + 3) seemed to be slightly more shielded at higher 
temperatures with the expected negative slopes (4.56 and 4.50).  These values are typical for peptide 
amide protons in the absence of hydrogen bond interactions.124-129  
The -Δδ/ΔT plots for both of the backbone amides of trans-2b, [Bz(NO)PMeGNF] are presented in 
Figure 2.22.  The hydrogen bond interaction between the amide proton (i + 2) and the N-oxide 
oxygen gave a positive slope (gradient = 1.49).  This value verified that the hydrogen bond was not 
as strong as for 1b (i + 1).  The observed gradient for the (i + 1) system in 1b was higher (gradient = 
2.64) than for the (i + 2) system in 2b (gradient = 1.49); the latter exhibited less temperature 
                                                 
















































dependence, most possibly due to the more flexible nature of the larger turn structure.  An important 
difference between the (i + 2) data for 1b and 2b was that the sign of the slopes indicative of 
substantial hydrogen bonding for 2b.  Blocking of the (i + 1) amide proton through N-methylation, 
therefore induces stronger hydrogen bond interaction between the N-oxide oxygen atom and the (i + 
2) amide proton.  
  
                                                 (1)                                                       (2) 
(1) HN-Asn (-Δδ/ΔT= -1.49 ppb/K)3, (2) HN-Phe (-Δδ/ΔT= 7.29 ppb/K) (R2 > 0.951 for all graphs) 
Figure 2.22.  The hydrogen bond investigation with thermal Coefficient plots for each amide 
protons of trans-2b, [Bz(NO)PMeGNF].  (Solvent: DMSO-d6), (temperature: 293-333 K)  
For the next amide (i + 3) of 2b, this slope was negative (-4.56 ppb/K) suggesting that hydrogen 
bonding also occurred between corresponding amide proton and the NO-.   
The -Δδ/ΔT plots for the backbone amides of trans-3b, [Bz(NO)PIVQ] are presented in Figure 
2.23.  The hydrogen bond interaction between the amide proton (i + 1) and the N-oxide oxygen 
resulted in a positive slope (gradient = 0.66).  This small value combined with the deshielding 
experienced by this proton (registered at about 12 ppm) suggested that the proton was being 
completely transferred from the donor to the acceptor.  In comparison to 1b, the slope for the (i + 1) 
system of 3b was much shallower.  A potential reason for that was the more rigid nature of peptide 
3b, allowing for substantial transfer of the amide proton to NO-, even at higher temperatures.  It 
therefore becomes an entropy argument130 where the corresponding system in 3b was more ordered.  
                                                 








































                                                  (2)                                                    (3) 
(1) HN-Ile (-Δδ/ΔT= -0.66 ppb/K)4 (2) HN-Val (-Δδ/ΔT= 5.98 ppb/K), (3) HN-Gln (-Δδ/ΔT= 5.04 
ppb/K) (R2 > 0.959 for all graphs) 
Figure 2.23.  The hydrogen bond investigation with thermal Coefficient plots for each amide of 
trans-3b, [Bz(NO)PIVQ].  (Solvent: DMSO-d6), (temperature: 293-333 K) 
The sign and values of the slopes of trans-3b for (i + 2) and (i + 3) clearly showed that these 
backbone amide protons were not involved in hydrogen bonding interactions.  
The case of 4b turned out to be unusual in terms of the behaviour observed so far.  The proton NMR 
spectrum for trans-4b exhibited no unusual deshielding of any of the amide protons (Figure 2.24).  
On the other hand, the cis-isomer displayed an amide proton at about 10 ppm.  The -Δδ/ΔT plots for 
cis-4b, [Bz P(NO) MeI V Q] illustrated hydrogen bonding interaction between the NH (i + 2) and 
the N-oxide oxygen, but it was not as strong as that observed for the corresponding system in 3b.  
The slope of this system is zero, indicating a strong hydrogen bond, but in the absence of acid-base 
equilibrium.   
                                                 
4 *Unusual zero slope of the HN-Ile plot is related to hydrogen bond in absence of acid-base equilibrium between the N-
















































                                                  (1)                                                    (2) 
(1) HN-Val (-Δδ/ΔT= 0 ppb/K), (2) HN-Gln (-Δδ/ΔT= 6.11 ppb/K) (R2 > 0.999 for all graphs) 
Figure 2.24.  The hydrogen bond investigation with thermal Coefficient plots for each amide of cis-
4b, [Bz(NO)PMeIVQ].  (Solvent: DMSO-d6), (temperature: 293-333 K) 
The sign and value of the slope of cis-4b for (i + 3) indicated that the proton did not experience 
hydrogen bond interactions, similar to the non-hydrogen bonded amides presented before.   
The presence of sterically hindered amino acids normally prevents the formation of hydrogen 
bonding interactions for weak acceptors such as carbonyl groups.  However, it can be concluded that 
for a strong acceptor like N-oxide oxygen when combined with N-methylation of the (i + 1) amide 
proton, the existence of bulky side chains in amino acids could still induce stronger hydrogen bond 
interaction for the (i + 2) system.  The possibility of more prominent cis-conformations is also 
possible.  
1.3 Experimental  
1.3.1 Materials and Methods.   
Fmoc-protected amino acids, CTC resin and HBTU were bought from GL-Biochem (Shanghai, 
China).  HPLC–grade CH3CN, MeOH and peptide synthesis-grade DMF, CH2Cl2, DIEA, TFA and 
all other reagents were purchased from Sigma-Aldrich (Germany).  Analytical reversed-phase HPLC 
was performed on a C18 column (4.6 × 150 mm, 5 μm, YMC Triart, UK) with a LC-MS 2020A 
system (Shimadzu, Kyoto, Japan).  Solvents A and B were 0.01% (v/v) formic acid in milli q water, 
and CH3CN, respectively.  Elution was achieved with linear 0-90% gradients of solvent B to A over 
15 minutes at 1 ml/min flow rate, with UV detection at 200 nm.  Preparative HPLC was performed 


































Solvents A and B were 0.1% formic acid (v/v) in water and MeOH, respectively and a linear 
gradient of solvent B to A over 40 minutes, at 15 mL/min flow rate was applied.  The UV detection 
wavelength was set at 200 nm.  Purified fractions (>95%) by HPLC were pooled and lyophilized.  
Purified peptides and conjugates were characterized with HRMS, on Bruker micrOTOF-Q II 
instrument operating at ambient temperatures and sample 1 ppm.  DMSO-d6 was used as a solvent 
for sample preparation of NMR.  H1 NMR, C13 NMR, COSY, HSQC, HMBC and ROESY 
experiments were performed at ambient temperature on AVANCE III 600 MHz NMR (Bruker, 
Germany).  To achieve better resolution in the NMR spectra, the water peak was suppressed in 
necessary cases. 
1.3.2 General procedure for the synthesis of the tetrapeptides.   
Peptides were manually synthesized on a 0.1 mmol scale on CTC resin (0.6 mmol/g).  The resin was 
activated using 10% thionylchloride (v/v) in dry DCM, after which incorporation of the C-terminal 
amino acids was performed with a minimum of four equivalents of Fmoc-amino acid and six 
equivalents of DIEA in dry DCM for 3 hrs.  Elongation of the peptide chains was achieved following 
standard Fmoc protocols.  The coupling conditions were: 5-fold molar excess of Fmoc-amino acid 
and HBTU, double molar excess of DIEA in DMF.  Deprotections were achieved with 20% 
piperidine in DMF (3 x 10 min).  Coupling of N-benzylproline was achieved employing the same 
method.  After chain assembly, total deprotection and cleavage was carried out with TFA/DCM 
(40:60) for one hour and the peptides were precipitated by adding chilled diethyl ether.  After 
evaporation to dryness, the solid forms of the crude peptides were obtained.  The crude peptides 
were purified via semi preparative HPLC and characterized using NMR and HRMS. 
1.3.3 General procedure for the preparation of N-oxide tetrapeptides.   
Crude peptide (0.1 mmol) and K2CO3 (2.5 equiv.) were dissolved in dry DCM (10 ml).  m-CPBA 
(1.6 equiv.) was added to a cooled solution mixture (-72 °C).  The reaction was stirred for four hours 
under the same conditions and warmed up to room temperature over two hours.  Finally, the solvent 
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2 Summary   
Two groups of peptide were investigated in this study.  The first group is designed to yield optimal 
turn characteristics.  In contrast, the second group possess sterically hindered residues that were 
selected to prevent the formation of turns in their peptide backbones.  
The members of first group were 1a, (BzPGNF) and 2a, (BzPMeGNF) and their corresponding N-
oxide peptides 1b, [Bz(NO)PGNF] and 2b, [Bz(NO)PMeGNF].  Phenylalanine, asparagine and 
glycine were chosen for this backbone from the C-terminal to N-terminal respectively, and finally N-
benzylproline was coupled to each.  
 
    R: H        1a, (BzPGNF)                                                       1b, [Bz(NO)PGNF] 
    R: Me     2a, (BzPMeGNF)                                                  2b, [Bz(NO)PMeGNF] 
 
    R: H         3a, (BzPIVQ)                                                     3b, [Bz(NO)PIVQ] 
    R: Me      4a, (BzPMeIVQ)                                                4b, [Bz(NO)PMeIVQ] 
Figure 3.1.  N-oxide-proline tetrapeptides. 
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As expected the amide groups of 1a and 1b possess trans-character.  1b did not exhibit extraordinary 
NOE correlations, which suggests that this peptide is too flexible or perhaps assumes an extended 
conformation.  The reaction between peptide 1a and m-CPBA at -72°C led to the oxidation of the 
tertiary amine of N-benzylproline introducing a N-oxide moiety in the peptide sequence, to form N-
oxide peptide 1b.  The 1H NMR spectrum of this peptide reveals the hydrogen bonding interaction 
between the amide proton of glycine and oxygen of N-oxide, suggesting the presence of a quasi γ-
turn in 1b.  A thermal coefficient NMR study was performed and the data confirmed this 
observation.  Interestingly, 1b exists as two conformers, one exhibiting a turn and another without.  
The population of the first conformer increases with elevated temperature suggesting that the turned 
structure is the kinetic product, while the proposed extended structure is the thermodynamic product.   
Further investigations were undertaken to determine if this hydrogen bond could create larger turns 
or not.  Therefore the first amide proton on glycine (i + 1) was blocked by N-methylation and thus 
peptide 2a was obtained.  In 2a, cis- and trans-isomers with an approximate ratio of 47:53 % 
respectively, were detected from the 1H NMR spectra.  In addition, it seems that none of those 
isomers exhibited any backbone turns.  The corresponding N-oxide peptide, 2b, was successfully 
synthesized and elucidated.  Peptide 2b presented two isomers according to the 1H NMR spectra 
with a cis- and trans-isomer ratio of 29:71 % respectively.  The downfield back bone amide proton 
of asparagine (i + 2) in the trans-isomer (major conformation) suggests a quasi β-turn due this 
hydrogen bonding interaction.  Additional thermal coefficient NMR experiments probing the nature 
of this hydrogen bond were performed.  
The second class of peptides had the sequence glutamine (i + 3), valine (i + 2), isoleucine (i + 1) and 
N-benzylproline from C-terminal to N-terminal, respectively.  Peptides 3a and 3b presented only 
trans-isomers and a quasi γ-turn was detected in 3b (hydrogen bond interaction between the first 
amide proton next to proline and N-oxide).  Interestingly, it seems that the presence of a bulkier 
amino acid in the (i + 1) position facilitates more stable hydrogen bonding interactions.  Thermal 
coefficient NMR results supported this observation.  
The final part of this study involved peptides 4a and 4b where they possess even more sterically 
hindered groups (N-methylated isoleucine was used as a (i + 1) residue).  In the case of 4a, we 
observed multiple isomers and the major and minor conformers were assigned as cis- and trans-
isomers (40:60 %), respectively.  In addition, a ROESY NMR experiment was used to elucidate each 
isomer and N-methyl proton integration was used to determine the ratio.  Peptide 4a did not 
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demonstrate any extraordinary NOE correlations, which suggests this sequence is either too flexible, 
or mostly in an extended form (β-sheet) in both isomers.  After inserting the N-oxide to the backbone 
yielding 4b as a product, a NMR investigation was performed to obtain a better understanding of the 
3D structure of this peptide.  Two isomers were observed resulting from a cis- and trans-
isomerization process (77:23 %).  The proton chemical shifts of 4b (major/cis) reveal that the amide 
proton of valine (i + 2) is involved in a hydrogen bonding interaction with the N-oxide group.  This 
contact is possible through a quasi β-turn, which is a novel achievement, especially in the presence 
of sterically hindered residues.  In addition, it seems that the hydrogen bond occurred only in the cis-
isomer perhaps explaining why it is observed as the major isomer, since stabilization of the 
secondary structure is increased through hydrogen bonding.  This hydrogen bond interaction was 
confirmed with a thermal coefficient NMR study of this peptide. 
Application of this novel structure characteristic in future studies should include testing of the 
bioactivity of such peptides as this turn decreases the peptide flexibility and the N-methylation 





 Isomers   Thermal coefficient study with NMR 
[-Δδ/ΔT (ppb/K)] 
Entry Sequence    N-Me NO-   cis (%) trans (%) 
Turn 
(γ or β) 
Presence of NOE 
correlations 
(i + 1) (i + 2) (i + 3) 
cis trans cis trans cis trans 
1a BzPGNF - - - 100 - - -  2.35 -  5.80 -   1.73 
1b   Bz(NO)PGNF -  - 100b γ - -    -2.64
M -  4.56M  -     
4.50M -   4.69
m -  4.71m -     2.43m 
2a BzPMeGNF  - 47 53 - - - -  4.68  3.88   4.72 5.2 
2b Bz(NO)PMeGNF   29 71 β  - - -a   -1.49c - a   7.29 
3a BzPIVQ - - - 100 - - - 5.52 -  5.63 -   2.21 
3b Bz(NO)PIVQ -  - 100 γ - - -0.66 -  5.98 -  5.04 
4a BzPMeIVQ  - 40 60 - - - - 6.54  3.36   5.74   3.39 
4b    Bz(NO)PMeIVQ   77 23 β  - - 0 - a   6.11 - a 
 
 
                                                 
M  The major product at room temperature with trans amide bond for (i + 1). 
m
  The minor product at room temperature with trans amide bond for (i + 1). 
a   This isomer was not elucidated due two low signal and overlapping with signal of major isomer. 
b   Two conformers with trans-isomer were assigned from 1H NMR spectra. 
c    The minus value for -Δδ/ΔT represents the existence of acid-base equilibrium in this hydrogen bond. 
